How to buy Equillium stock (EQ)

Equillium is a biotechnology business based in the US. Equillium shares (EQ) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.69 – an increase of 14.14% over the previous week. Equillium employs 45 staff and has a trailing 12-month revenue of around $42.6 million.

Our top picks for where to buy Equillium stock

Buy Equillium stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Equillium stock price (NASDAQ: EQ)

Use our graph to track the performance of EQ stocks over time.

Equillium shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$0.69
52-week range	$0.56 - $3.25
50-day moving average more info button	$0.82
200-day moving average more info button	$1.13
Wall St. target price	$3.33
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.12

Is it a good time to buy Equillium stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Equillium price performance over time

Historical closes compared with the close of $0.631 from 2024-12-26

1 week (2024-12-20)	3.78%
1 month (2024-11-27)	-18.05%
3 months (2024-09-27)	-24.18%
6 months (2024-06-27)	-5.54%

1 year (2023-12-27)	-3.09%
2 years (2022-12-27)	-24.88%
3 years (2021-12-27)	4.11
5 years (2019-12-27)	4.03

Equillium financials

Revenue TTM	$42.6 million
Gross profit TTM	$15.8 million
Return on assets TTM	-11.95%
Return on equity TTM	-33.67%
Profit margin	-19.51%
Book value	$0.64
Market Capitalization more info button	$22.4 million

TTM: trailing 12 months

Equillium share dividends

We're not expecting Equillium to pay a dividend over the next 12 months.

Equillium share price volatility

Over the last 12 months, Equillium's shares have ranged in value from as little as $0.5605 up to $3.25. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Equillium's is 1.826. This would suggest that Equillium's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Equillium overview

Equillium, Inc. , a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. Equillium, Inc. has a research collaboration agreement with Vivtex Corporation to develop GI-targeted formulations for Bi-specific peptide therapy.

Frequently asked questions

null
What percentage of Equillium is owned by insiders or institutions?
Currently 36.205% of Equillium shares are held by insiders and 20.038% by institutions. How many people work for Equillium?
Latest data suggests 45 work at Equillium. When does the fiscal year end for Equillium?
Equillium's fiscal year ends in December. Where is Equillium based?
Equillium's address is: 2223 Avenida De La Playa, La Jolla, CA, United States, 92037 What is Equillium's ISIN number?
Equillium's international securities identification number is: US29446K1060 What is Equillium's CUSIP number?
Equillium's Committee on Uniform Securities Identification Procedures number is: 29446K106